Property:Outcome timeline
This is a property of type Text.
A
Afonseca et al. (2013): Vitamin E for prevention of oxaliplatin-induced peripheral neuropathy: A pilot randomized clinical trial +
NI +
Akiba et al. (2018): Vitamin D Supplementation and Survival of Patients with Non–small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial +
T0: Baseline +
Ansari et al. (2016): Efficacy of Ginger in Control of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients Receiving Doxorubicin- Based Chemotherapy +
NI +
T0: baseline before first cycle of chemotherapy
afterwards: observation over 2 years or until death +
Arbabi-kalati et al. (2012): Evaluation of the efficacy of zinc sulfate in the prevention of chemotherapy-induced mucositis: A double-blind randomized clinical trial +
T0: Baseline (before chemotherapy)
T1: after 2 weeks
T2: after 4 weeks
T3: after 6 weeks
T4: after 8 weeks
T5: after 10 weeks
T6: after 12 weeks
T7: after 14 weeks
T8: after 16 weeks
T9: after 18 weeks
T10: after 20 weeks +
Argyriou et al. (2006): A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results +
T0: Baseline
T1 or T2: after 3rd or 6th chemotherapy cycle
T3: 3 months post-chemotherapy +
Argyriou et al. (2006): Preventing Paclitaxel-Induced Peripheral neuropathy: A Phase 2 Trial of Vitamin E Supplementation +
T0: Baseline
T1 or T2: after 3rd or 6th chemotherapy cycle
T3: 3 months post-chemotherapy +
Arslan et al. (2015): Oral Intake of Ginger for Chemotherapy-Induced Nausea and Vomiting Among Women With Breast Cancer +
T1: Day 1 (i.e. day of the chemotherapy infusion)
T2: Day 2 (i.e. day after chemotherapy infusion)
T3: Day 3
T4: Day 4
T5: Day 5 +
Asfour et al. (2006): Effect of high-dose sodium selenite therapy on polymorphonuclear leukocyte apoptosis in non-Hodgkin's lymphoma patients +
T0: Baseline
T1: Day 3
T2: Day 8 +
Attia et al. (2008): Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer +
T0: Baseline
On day 1 of every 28-day cycle +
Azizi et al. (2015): Efficacy of Topical and Systemic Vitamin E in Preventing Chemotherapy-induced Oral Mucositis +
T0: Baseline
T1: after first cycle
T2: after second cycle
T3: after third cycle
T4: after fourth cycle +
B
Bairati et al. (2005): A Randomized Trial of Antioxidant Vitamins to Prevent Second Primary Cancers in Head and Neck Cancer Patients +
T0: before radiotherapy
T1: during radiotherapy
T2: immediately post-radiotherapy
T3: 1 month post-radiotherapy
from T4: every 6 months for 3 years, then once a year until 30.06.2003 +
Bairati et al. (2005): Randomized Trial of Antioxidant Vitamins to Prevent Acute Adverse Effects of Radiation Therapy in Head and Neck Cancer Patients +
T0: before radiotherapy
T1: during radiotherapy
T2: immediately post-radiotherapy
T3: 1 month post-radiotherapy
from T4: every 6 months for 3 years, then once a year until 30.06.2003 +
Bairati et al. (2006): Antioxidant vitamins supplementation and mortality: a randomized trial in head and neck cancer patients +
T0: before radiotherapy
T1: during radiotherapy
T2: immediately post-radiotherapy
T3: 1 month post-radiotherapy
from T4: every 6 months for 3 years, then once a year until 30.06.2003 +
Barton et al. (1998): Prospective evaluation of vitamin E for hot flashes in breast cancer survivors +
T0: Week -1 Vitamin E (measured for 1 week)
T1: after 4 weeks
T2: after 8 weeks +
Barton et al. (2013): The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9 +
Baseline (before first or second cycle of chemotherapy), during chemotherapy, at the first visit postchemotherapy (generally 1 month after chemotherapy and commensurate with the completion of the study agent), and at 6, 12, 18, and 24 months after chemotherapy. Potential side effects were evaluated at each data point. +
Beer et al. (2007): Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators +
Every 4 weeks +
Bossi et al. (2017): A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin +
T1: Cycle 1 (day 2 to day 21 or 28)
T2: Cycle 2 (day 23 or 30 to day 42 or 56) +
Braga et al. (2015): Effect of Zinc Supplementation on Serological Response to Vaccination Against Streptococcus Pneumoniae in Patients Undergoing Chemotherapy for Colorectal Cancer +
T0: perioperative (prior to vaccination)
T1: before the chemotherapy (4th wk of study)
T2: after 3 cycles of chemotherapy (16th wk of study) +
Braik et al. (2014): Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy +
T1-T4: week 3 of each chemotherapy cycle +